MA47198A - Combinaison d'un inhibiteur de mcl-1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant - Google Patents

Combinaison d'un inhibiteur de mcl-1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant

Info

Publication number: MA47198A
Authority: MA; Morocco
Prior art keywords: mcl; inhibitor; combination; pharmaceutical compositions; compositions including
Prior art date: 2017-01-06

Application number

MA047198A

Other languages

English (en)

Inventor

Maïa Chanrion

Olivier Geneste

Ensar Halilovic

Guillaume Lessene

Geoffrey Lindeman

Ana Leticia Maragno

Elisabetta Marangoni

Delphine Merino

Dale Porter

François Vaillant

Jane Visvader

James Whittle

Original Assignee

Servier Lab

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-06

Filing date

2018-01-05

Publication date

2019-11-13

2018-01-05 Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab

2019-11-13 Publication of MA47198A publication Critical patent/MA47198A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

MA047198A 2017-01-06 2018-01-05 Combinaison d'un inhibiteur de mcl-1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant MA47198A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201762443082P	2017-01-06	2017-01-06
EP17157779		2017-02-24
US201762527360P	2017-06-30	2017-06-30

Publications (1)

Publication Number	Publication Date
MA47198A true MA47198A (fr)	2019-11-13

Family

ID=61007674

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047198A MA47198A (fr)	2017-01-06	2018-01-05	Combinaison d'un inhibiteur de mcl-1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant

Country Status (20)

Country	Link
US (1)	US10765680B2 (fr)
EP (1)	EP3565547B1 (fr)
JP (1)	JP7179733B2 (fr)
KR (1)	KR102576567B1 (fr)
CN (1)	CN110381937A (fr)
AU (1)	AU2018205735B2 (fr)
BR (1)	BR112019013907A2 (fr)
CA (1)	CA3049095C (fr)
CL (1)	CL2019001859A1 (fr)
CO (1)	CO2019007261A2 (fr)
CU (1)	CU20190064A7 (fr)
GE (1)	GEP20227372B (fr)
IL (1)	IL267791B (fr)
JO (1)	JOP20190159B1 (fr)
MA (1)	MA47198A (fr)
MX (1)	MX2019008109A (fr)
PH (1)	PH12019501451A1 (fr)
RU (1)	RU2763544C2 (fr)
UA (1)	UA125142C2 (fr)
ZA (1)	ZA201904280B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2020254299A1 (fr) *	2019-06-17	2020-12-24	Les Laboratoires Servier	Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers du sein, utilisations et compositions pharmaceutiques associées

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100870314B1 (ko) *	2008-02-19	2008-11-25	고려대학교 산학협력단	암 치료용 핵산 의약 조성물
EP2684167B1 (fr) *	2011-03-08	2020-09-09	Eutropics Pharmaceuticals, Inc.	Compositions et méthodes utiles dans le traitement de maladies
FR3015483B1 (fr) *	2013-12-23	2016-01-01	Servier Lab	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105311016A (zh)	2014-07-24	2016-02-10	中国科学院大连化学物理研究所	一种抗细胞凋亡Mcl-1蛋白抑制剂及其应用
FR3037958B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) *	2016-01-19	2018-02-02	Les Laboratoires Servier	Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2019026819A1 (fr) *	2017-08-02	2019-02-07	株式会社村田製作所	Actionneur

2018
- 2018-01-05 AU AU2018205735A patent/AU2018205735B2/en active Active
- 2018-01-05 JO JOP/2019/0159A patent/JOP20190159B1/ar active
- 2018-01-05 BR BR112019013907A patent/BR112019013907A2/pt active Search and Examination
- 2018-01-05 KR KR1020197022996A patent/KR102576567B1/ko active IP Right Grant
- 2018-01-05 MX MX2019008109A patent/MX2019008109A/es unknown
- 2018-01-05 US US16/475,389 patent/US10765680B2/en active Active
- 2018-01-05 JP JP2019536593A patent/JP7179733B2/ja active Active
- 2018-01-05 MA MA047198A patent/MA47198A/fr unknown
- 2018-01-05 UA UAA201907499A patent/UA125142C2/uk unknown
- 2018-01-05 CU CU2019000064A patent/CU20190064A7/es unknown
- 2018-01-05 CN CN201880015906.7A patent/CN110381937A/zh active Pending
- 2018-01-05 GE GEAP201815157A patent/GEP20227372B/en unknown
- 2018-01-05 EP EP18700861.0A patent/EP3565547B1/fr active Active
- 2018-01-05 RU RU2019123982A patent/RU2763544C2/ru active
- 2018-01-05 CA CA3049095A patent/CA3049095C/fr active Active
2019
- 2019-06-21 PH PH12019501451A patent/PH12019501451A1/en unknown
- 2019-06-28 ZA ZA2019/04280A patent/ZA201904280B/en unknown
- 2019-07-02 IL IL267791A patent/IL267791B/en unknown
- 2019-07-04 CL CL2019001859A patent/CL2019001859A1/es unknown
- 2019-07-05 CO CONC2019/0007261A patent/CO2019007261A2/es unknown

Also Published As

Publication number	Publication date
US20190336505A1 (en)	2019-11-07
CU20190064A7 (es)	2020-02-04
RU2019123982A3 (fr)	2021-03-25
BR112019013907A2 (pt)	2020-02-04
KR20190103317A (ko)	2019-09-04
IL267791B (en)	2022-02-01
CA3049095C (fr)	2022-01-25
KR102576567B1 (ko)	2023-09-07
RU2763544C2 (ru)	2021-12-30
IL267791A (en)	2019-09-26
CA3049095A1 (fr)	2018-07-12
US10765680B2 (en)	2020-09-08
PH12019501451A1 (en)	2020-06-01
CL2019001859A1 (es)	2019-11-15
EP3565547A1 (fr)	2019-11-13
MX2019008109A (es)	2019-09-04
JP2020503361A (ja)	2020-01-30
AU2018205735A1 (en)	2019-07-11
CN110381937A (zh)	2019-10-25
UA125142C2 (uk)	2022-01-19
EP3565547B1 (fr)	2024-03-13
KR102576567B9 (ko)	2023-12-15
GEP20227372B (en)	2022-04-25
JOP20190159A1 (ar)	2019-06-25
JP7179733B2 (ja)	2022-11-29
AU2018205735B2 (en)	2024-02-01
RU2019123982A (ru)	2021-02-08
CO2019007261A2 (es)	2019-07-31
ZA201904280B (en)	2022-03-30
JOP20190159B1 (ar)	2023-09-17

Similar Documents

Publication	Publication Date	Title
CO2020007244A2 (es)	2020-10-30	Inhibidores de kras g12c
GEP20237506B (en)	2023-05-25	Pcsk9 antagonist compounds
MX2018001990A (es)	2018-06-19	Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MA47743A (fr)	2020-01-15	Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
EA202091256A1 (ru)	2020-10-05	Новые антагонисты рецептора брадикинина
EA201791454A1 (ru)	2017-12-29	Лекарственные формы для трансдермального введения
EA201891644A1 (ru)	2019-04-30	Антибактериальные соединения и их применение
UY37560A (es)	2018-07-31	Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CY1123408T1 (el)	2021-12-31	Φαρμακευτικες συνθεσεις και χρηση των αυτων
MA45718A (fr)	2019-05-29	Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
MA54222A (fr)	2021-09-22	Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées
BR112015011351A2 (pt)	2017-07-11	composição farmacêutica de difenidol de liberação sustentada
MA49947A (fr)	2021-04-21	Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA47198A (fr)	2019-11-13	Combinaison d'un inhibiteur de mcl-1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant
MA49444A (fr)	2020-04-29	Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées
EA201990162A1 (ru)	2019-06-28	Фармацевтические композиции
EA201791483A1 (ru)	2017-11-30	Фармацевтическая композиция для лечения микоза
EA201991623A1 (ru)	2020-01-15	Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
BR112016022439A2 (pt)	2017-08-15	Composições farmacêuticas que compreendem cefepima ou sulbactama
MA55446A (fr)	2022-02-09	Co-cristal de kétoprofène et sa préparation, compositions pharmaceutiques le contenant et ses utilisations
TR201722970A2 (tr)	2019-07-22	Flurbi̇profen-li̇dokai̇n ve seti̇lpi̇ri̇di̇nyum i̇çeren farmasöti̇k bi̇leşi̇mler
EA201990305A1 (ru)	2019-07-31	Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
TR201720672A2 (tr)	2019-07-22	İvabradi̇ni̇n kontrollü salimli farmasöti̇k kompozi̇syonlari
UA112035C2 (uk)	2016-07-11	2-ізопропіл-5-метилциклогексил-4-амінобутирату гідрохлорид, що проявляє протисудомну та седативну активність
UA117523C2 (uk)	2018-08-10	Активна біологічна субстанція, отриманий на її основі препарат місцевої дії